Sandbox:Preeti: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 337: Line 337:
! rowspan="3" align="center" style="background:#DCDCDC;" + |Marginal zone lymphoma
! rowspan="3" align="center" style="background:#DCDCDC;" + |Marginal zone lymphoma
! align="center" style="background:#DCDCDC;" + |Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type
! align="center" style="background:#DCDCDC;" + |Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type
|
| align="left" style="background:#F5F5F5;" + |
* Mature B-cell Lymphoma
* Mature B-cell Lymphoma
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 468: Line 468:
|
|
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Hairy cell leukemia]]
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Hairy cell leukemia]]
|
| align="left" style="background:#F5F5F5;" + |
* Production of [[Cytokine|cytokines]], such as [[TNF alpha]] and IL-2R, provide important stimuli for [[malignant]] [[B cell|B cells]] proliferation in hairy cell leukemia.
* Production of [[Cytokine|cytokines]], such as [[TNF alpha]] and IL-2R, provide important stimuli for [[malignant]] [[B cell|B cells]] proliferation in hairy cell leukemia.
** The ''p38-MAPK-JNK'' cascade  
** The ''p38-MAPK-JNK'' cascade  
** The ''MEK-ERK'' cascade  
** The ''MEK-ERK'' cascade  
** The ''Phosphatidylinositol 3 kinase (PI3K)-AKT'' cascade
** The ''Phosphatidylinositol 3 kinase (PI3K)-AKT'' cascade
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="left" style="background:#F5F5F5;" + |
* [[Fever]]
* [[Fever]]
* [[Night sweat|Night sweats]]
* [[Night sweat|Night sweats]]
Line 486: Line 486:
* Recurrent [[Infection|infections]]
* Recurrent [[Infection|infections]]
* Early satiety
* Early satiety
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="left" style="background:#F5F5F5;" + |
* [[Pallor]],
* [[Pallor]],
* [[Petechiae]]
* [[Petechiae]]
* [[Splenomegaly]]
* [[Splenomegaly]]
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="left" style="background:#F5F5F5;" + |
* Tartrate-resistant acid phosphatase positive
* Tartrate-resistant acid phosphatase positive
* CBC
* CBC
** Decreased [[hemoglobin]] concentration
** Decreased [[hemoglobin]] concentration
** Decreased [[platelets]] count
** Decreased [[platelets]] count
**  
**  
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="left" style="background:#F5F5F5;" + |
* [[Annexin A1]]  
* [[Annexin A1]]  
* [[CD20]]  
* [[CD20]]  
Line 515: Line 515:
* [[CD11c]]  
* [[CD11c]]  
* [[FMC7]]  
* [[FMC7]]  
|
| align="left" style="background:#F5F5F5;" + |
:* Small cells with "fried egg"-like appearance
* Small cells with "fried egg"-like appearance
:* Well-demarcated thread-like [[cytoplasmic]] extensions
* Well-demarcated thread-like [[cytoplasmic]] extensions
:* Clear cytoplasm
* Clear cytoplasm
:* Central round [[nucleus]]
* Central round [[nucleus]]
:* Peri-nuclear clearing ("water-clear rim" appearance)
* Peri-nuclear clearing ("water-clear rim" appearance)
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|-
|-
|
|
! colspan="2" align="center" style="background:#DCDCDC;" + |Precursor T-cell lymphoblastic leukemia/lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" + |Precursor T-cell lymphoblastic leukemia/lymphoma
|
| align="left" style="background:#F5F5F5;" + |
* Precursor T-cell Lymphomas
* Precursor T-cell Lymphomas
 
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
|-
|-
|
|
! colspan="2" align="center" style="background:#DCDCDC;" + |Adult T cell leukemia/lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" + |Adult T cell leukemia/lymphoma
|
| align="left" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|-
|-
|T cell lymphoma
|T cell lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" + |Anaplastic large cell lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" + |Anaplastic large cell lymphoma
|
| align="left" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|-
|-
|
|
! align="center" style="background:#DCDCDC;" + |Cutaneous T-cell lymphoma
! align="center" style="background:#DCDCDC;" + |Cutaneous T-cell lymphoma
! align="center" style="background:#DCDCDC;" + |[[Mycosis fungoides]] / [[Sézary syndrome]]
! align="center" style="background:#DCDCDC;" + |[[Mycosis fungoides]] / [[Sézary syndrome]]
|
| align="left" style="background:#F5F5F5;" + |
* The [[tumor]] [[Cell (biology)|cells]] originate from [[memory T cells]] or [[skin]] homing [[CD4+ T cells]] expressing [[cutaneous]] [[lymphocyte]] [[antigen]] (CLA) and [[chemokine]] [[receptors]] [[CCR4]]<nowiki/>and CCR7.
* The [[tumor]] [[Cell (biology)|cells]] originate from [[memory T cells]] or [[skin]] homing [[CD4+ T cells]] expressing [[cutaneous]] [[lymphocyte]] [[antigen]] (CLA) and [[chemokine]] [[receptors]] [[CCR4]]<nowiki/>and CCR7.
* It is understood that cutaneous t cell lymphoma (maycosis fungoides, Sezary sydrome ) is the result of malignant T cell that derived from a mature CD41 CD45RO1 memory T cells.
* It is understood that cutaneous t cell lymphoma (maycosis fungoides, Sezary sydrome ) is the result of malignant T cell that derived from a mature CD41 CD45RO1 memory T cells.
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="left" style="background:#F5F5F5;" + |
* [[Epidermis (skin)|Epidermal]] [[atrophy]] or poikiloderma
* [[Epidermis (skin)|Epidermal]] [[atrophy]] or poikiloderma
* Generalized [[itching]]([[pruritus]])
* Generalized [[itching]]([[pruritus]])
Line 629: Line 628:
* [[Anemia]]
* [[Anemia]]
* May progress to [[Sezary syndrome]] (Skin involvement plus hematogenous dissemination)
* May progress to [[Sezary syndrome]] (Skin involvement plus hematogenous dissemination)
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="left" style="background:#F5F5F5;" + |
* Cutaneous manifestations
* Cutaneous manifestations
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|-
|-
|
|

Revision as of 19:00, 7 January 2019


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]

Category Disease Etiology Mechanism Clinical manifestations Paraclinical findings Gold standard Associated findings
Lab findings
Demography History Symptoms Signs CBC PBS PT/PTT Immunochemistry Histopathology Other
Inherited Acquired Constitutional symptoms Rash Abdominal pain Diarrhea V/S Mass LAP Hepatosplenomegaly Other WBC Hb Plt
HL
Hodgkin's Lymphoma
NHL
B Cell Lymphoma Precursor B-cell lymphoblastic leukemia/lymphoma
  • Precursor B-cell Lymphoma
Follicular lymphoma
  • Mature B-cell Lymphoma
  • Reciprocal translocation t(14;18)(q32;q21)
  • Second most common subtype of NHL
+ +
  • Painless swelling in the neck, axilla, groin, thorax and abdomen
  • Central and peripheral lymphadenopathy
+
  • Most common clinically indolent NHL
Mantle cell lymphoma
  • Fatigue
  • Night sweats
  • Weight Loss
Abdominal distention
  • Palpable masses in skin, breast, and salivary glands
Generalized lymphadenopathy +
  • Extranodal involvement of GI tract, lungs, and CNS
  • Mental Retardation
  • Lymphocytosis > 4000/µL
Nl to ↓
  • CD5+
  • B-cell antigen positive
  • Overexpression of Cyclin D1
  • Germinal centers filled by small-to-medium atypical lymphocytes
  • Nodular appearance
Elevated LDH
Diffuse large B cell lymphoma
  • Mature B-cell Lymphoma
  • 8q24/MYC translocations
  • Hypermutated immunoglobulin genes
  • Mutation of BCL6, MYC, PAX5, PIM1, RhoH /TTFn, TP53 genes
  • Translocations involving c-MYC, BCL6, and IgH gene.
  • Fever
  • Night sweats
  • weight loss
Nl to ↓

Centroblastic

Immunoblastic

  • > 90% immunoblasts
  • Trapezoid shaped large lymphoid cells with significant basophilic cytoplasm

Anaplastic

  • Very large cells with a round, oval, or polygonal shape that may resemble Reed-Sternberg cells
  • Hypergammaglobulinemia
Category Disease Etiology Inherited Acquired Demography History Constitutional symptoms Rash Abdominal pain Diarrhea V/S Mass LAP Hepatosplenomegaly Other WBC Hb Plt PBS PT/PTT Immunochemistry Histopathology Other lab findings Gold standard Associated findings
Burkitt lymphoma
  • Mature B-cell Lymphoma
  • Translocation of chromosome 8 myc locus such as:
    • t(8;14)
    • t(2;8)
    • t(8;22)
  • Round and small nucleoli
  • basophilic cytoplasm
  • "Starry-sky pattern"
B cell chronic lymphocytic leukemia/small lymphocytic lymphoma
  • Mature B-cell Lymphoma
Marginal zone lymphoma Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type
  • Mature B-cell Lymphoma
Splenic marginal zone lymphoma
  • Mature B-cell Lymphoma
  • Clonal rearrangements of the immunoglobulin genes (heavy and light chains)
    • Deletion 7q21-32
    • Translocations of the CDK6 gene located on 7q21
  • Small lymphocytes
  • Transformed blasts
  • Epithelial histocytes
  • Plasmacytic differentiation of neoplastic cells
Nodal marginal zone B-cell lymphoma
  • Mature B-cell Lymphoma
  • Stimulation of antigen receptor by autoantigen and co-stimulatory molecule CD40
+
  • Hemorrhage
  • Dyspepsia
  • AE1/AE3
  • Expression of B-cell markers CD20, CD79a, CD10, CD23, and bcl-2
  • Follicular cells in reactive zone
  • Centrocyte like cells in marginal zone lymphoma
  • Chronic infectious conditions or autoimmune processes, such as
    • H pylori gastritis
  • Hashimoto thyroiditis
  • Sjögren syndrome
Lymphoplasmacytic lymphoma (Waldenstrom’s macroglobulinemia)
  • Mature B-cell Lymphoma
Hairy cell leukemia
  • Production of cytokines, such as TNF alpha and IL-2R, provide important stimuli for malignant B cells proliferation in hairy cell leukemia.
    • The p38-MAPK-JNK cascade
    • The MEK-ERK cascade
    • The Phosphatidylinositol 3 kinase (PI3K)-AKT cascade
  • Tartrate-resistant acid phosphatase positive
  • CBC
  • Small cells with "fried egg"-like appearance
  • Well-demarcated thread-like cytoplasmic extensions
  • Clear cytoplasm
  • Central round nucleus
  • Peri-nuclear clearing ("water-clear rim" appearance)
Precursor T-cell lymphoblastic leukemia/lymphoma
  • Precursor T-cell Lymphomas
Adult T cell leukemia/lymphoma
T cell lymphoma Anaplastic large cell lymphoma
Cutaneous T-cell lymphoma Mycosis fungoides / Sézary syndrome
  • Cutaneous manifestations
Peripheral T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma
Hepatosplenic gamma-delta T-cell lymphoma
Enteropathy-type intestinal T-cell lymphoma
Extranodal T-cell lymphoma, nasal type
Angioimmunoblastic T-cell lymphoma
Peripheral T-cell lymphoma, unspecified